Successful Tepotinib Rechallenge after Tepotinib-induced Adverse Events Following Pembrolizumab Failure in a Case of Non-small Cell Lung Carcinoma with MET Exon 14 Skipping

We herein report a case of successful rechallenge with tepotinib after tepotinib-induced adverse events following first-line treatment failure with pembrolizumab in a patient with non-small cell lung carcinoma harboring MET exon 14 skipping mutations. Initial tepotinib administration was suspended because of hepatotoxicity and hypersensitivity. However, the re-administration of tepotinib after a prolonged interval from pembrolizumab administration achieved sustained disease control. The patient continued tepotinib treatment for approximately two years after the first administration. Therefore, the treatment sequence should be considered based on comprehensive multigene testing results to achieve better therapeutic benefits.